Vaccine development :: from concept to clinic /
Utilising successful case studies Vaccine Development will provide insight to the issues scientists face when producing a vaccine, the steps involved and will serve as an ideal reference tool regarding state-of-the-art vaccine development.
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Cambridge :
Royal Society of Chemstry,
2022.
|
| Schriftenreihe: | RSC Drug development and pharmaceutical science.
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | Utilising successful case studies Vaccine Development will provide insight to the issues scientists face when producing a vaccine, the steps involved and will serve as an ideal reference tool regarding state-of-the-art vaccine development. |
| Beschreibung: | 1 online resource |
| ISBN: | 9781839162589 1839162589 9781839162572 1839162570 |
Internformat
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-on1350707644 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr |n||||||||| | ||
| 008 | 221113s2022 enk o 000 0 eng d | ||
| 040 | |a YDX |b eng |e rda |c YDX |d N$T |d UIU |d EBLCP |d UKRSC |d UKAHL |d OCLCF |d OCLCO |d GZM | ||
| 019 | |a 1354281945 | ||
| 020 | |a 9781839162589 |q (electronic bk.) | ||
| 020 | |a 1839162589 |q (electronic bk.) | ||
| 020 | |a 9781839162572 | ||
| 020 | |a 1839162570 | ||
| 020 | |z 9781788018777 | ||
| 020 | |z 178801877X | ||
| 035 | |a (OCoLC)1350707644 |z (OCoLC)1354281945 | ||
| 037 | |a 6102:5944 |b Royal Society of Chemistry |n http://www.rsc.org/spr | ||
| 050 | 4 | |a RM281 | |
| 072 | 7 | |a MED |x 071000 |2 bisacsh | |
| 072 | 7 | |a SCI |x 013040 |2 bisacsh | |
| 082 | 7 | |a 615.3/72 |2 23 | |
| 049 | |a MAIN | ||
| 245 | 0 | 0 | |a Vaccine development : |b from concept to clinic / |c edited by A. Krishna Prasad. |
| 260 | |a Cambridge : |b Royal Society of Chemstry, |c 2022. | ||
| 300 | |a 1 online resource | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Drug development and pharmaceutical science | |
| 505 | 0 | |a Cover -- Dedication -- Foreword -- Contents -- Chapter 1 Vaccine Development: From Concept to Clinic -- 1.1 Introduction -- 1.2 Preclinical Safety Assessment Considerations -- 1.3 Clinical Trials in the Development of Vaccines -- 1.5 High-throughput Assays for Clinical Development -- 1.6 Complexity in the Development of Multivalent Vaccines: Virus-like Particle-based Vaccines -- 1.7 Cell Culture-based Influenza Vaccine Development -- 1.8 Conjugate Vaccines: Design and Development Considerations -- 1.9 Vaccine Adjuvants | |
| 505 | 8 | |a 1.10 Development Considerations for Final Dosage Forms: Mucosal Bacterial Vaccines -- 1.11 Exploiting Glycans for Vaccine Design -- 1.12 Public-Private Partnerships for Vaccine Development -- 1.13 Structure-based Vaccine Design: The New Frontier -- 1.14 Vaccines to Target Antimicrobial Resistance -- 1.15 Technologies Revolutionizing Vaccines -- 1.15.1 Vaccines Based on Nucleic Acids -- 1.15.2 VLPs Produced from Plants -- 1.16 Vaccines Targeting Latent Viruses -- 1.16.1 Vaccines Targeting Shingles -- 1.16.2 Human Cytomegalovirus (CMV) -- 1.16.3 Epstein-Barr Virus (EBV) | |
| 505 | 8 | |a 1.17 The Unmet Medical Need -- 1.18 Herd Immunity -- References -- Chapter 2 Preclinical Safety Assessment Considerations for Vaccine Development -- Introduction -- 2.2 General Considerations -- 2.2.1 Regulatory Guidelines for the Non-clinical Safety Assessment of Vaccines and Adjuvants -- 2.2.2 Vaccine Modalities -- 2.2.3 Antigen -- 2.2.4 Adjuvant -- 2.3 Vaccine Study Design -- 2.3.1 Test Article -- 2.3.2 Species Selection -- 2.3.3 Study Groups -- 2.3.4 Dose, Dose Volume, and Administration Location -- 2.3.5 Dose Number and Dosing Interval -- 2.3.6 In-life Assessments | |
| 505 | 8 | |a 2.3.7 Anatomical Pathology -- 2.4 Genotoxicity and Carcinogenicity Studies -- 2.5 Biodistribution Studies -- 2.6 Neurovirulence Studies -- 2.7 Reproductive Toxicology Studies -- 2.8 Conclusion -- References -- Chapter 3 Clinical Trials in the Development of Vaccines for Infectious Diseases -- 3.1 Types of Vaccines and Populations for Immunisation -- 3.2 Staging Clinical Trials Throughout a Development Programme -- 3.3 Immunogenicity -- 3.3.1 Types of Antibody Assay -- 3.3.2 How Antibody Values are Expressed -- 3.3.3 What Does an Antibody Response Mean? | |
| 505 | 8 | |a 3.3.4 CellularMethods for Assessing Immunogenicity -- 3.3.5 Limits to Blood Sample Volumes -- 3.3.6 Clinical Trials That Use Immunogenicity Endpoints -- 3.4 Efficacy -- 3.4.1 Defining Efficacy -- 3.4.2 Defining Cases Within an Efficacy Trial -- 3.4.3 Selection of Subjects for Efficacy Trials -- 3.4.4 Efficacy Study Design -- 3.4.5 Non-pivotal Efficacy Studies -- 3.4.6 Controlled Human Infection Models -- 3.5 Safety -- 3.5.1 Reactogenicity -- 3.5.2 Other Adverse Events -- 3.6 Conclusion -- Postscript -- References -- Chapter 4 Clinical Trials in Immunotherapeutic Vaccine Development | |
| 520 | |a Utilising successful case studies Vaccine Development will provide insight to the issues scientists face when producing a vaccine, the steps involved and will serve as an ideal reference tool regarding state-of-the-art vaccine development. | ||
| 650 | 0 | |a Vaccines. |0 http://id.loc.gov/authorities/subjects/sh85141718 | |
| 650 | 0 | |a Drug development. |0 http://id.loc.gov/authorities/subjects/sh97007921 | |
| 650 | 2 | |a Vaccines |0 https://id.nlm.nih.gov/mesh/D014612 | |
| 650 | 6 | |a Vaccins. | |
| 650 | 6 | |a Médicaments |x Développement. | |
| 650 | 7 | |a Drug development |2 fast | |
| 650 | 7 | |a Vaccines |2 fast | |
| 700 | 1 | |a Prasad, A. Krishna, |e editor. | |
| 776 | 0 | 8 | |i Print version: |z 9781788018777 |w (OCoLC)1197720173 |
| 830 | 0 | |a RSC Drug development and pharmaceutical science. | |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=3453660 |3 Volltext |
| 938 | |a Askews and Holts Library Services |b ASKH |n AH39380813 | ||
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL7152694 | ||
| 938 | |a YBP Library Services |b YANK |n 303250344 | ||
| 938 | |a EBSCOhost |b EBSC |n 3453660 | ||
| 938 | |a YBP Library Services |b YANK |n 18383957 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-on1350707644 |
|---|---|
| _version_ | 1816882566336086016 |
| adam_text | |
| any_adam_object | |
| author2 | Prasad, A. Krishna |
| author2_role | edt |
| author2_variant | a k p ak akp |
| author_facet | Prasad, A. Krishna |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RM281 |
| callnumber-raw | RM281 |
| callnumber-search | RM281 |
| callnumber-sort | RM 3281 |
| callnumber-subject | RM - Therapeutics and Pharmacology |
| collection | ZDB-4-EBA |
| contents | Cover -- Dedication -- Foreword -- Contents -- Chapter 1 Vaccine Development: From Concept to Clinic -- 1.1 Introduction -- 1.2 Preclinical Safety Assessment Considerations -- 1.3 Clinical Trials in the Development of Vaccines -- 1.5 High-throughput Assays for Clinical Development -- 1.6 Complexity in the Development of Multivalent Vaccines: Virus-like Particle-based Vaccines -- 1.7 Cell Culture-based Influenza Vaccine Development -- 1.8 Conjugate Vaccines: Design and Development Considerations -- 1.9 Vaccine Adjuvants 1.10 Development Considerations for Final Dosage Forms: Mucosal Bacterial Vaccines -- 1.11 Exploiting Glycans for Vaccine Design -- 1.12 Public-Private Partnerships for Vaccine Development -- 1.13 Structure-based Vaccine Design: The New Frontier -- 1.14 Vaccines to Target Antimicrobial Resistance -- 1.15 Technologies Revolutionizing Vaccines -- 1.15.1 Vaccines Based on Nucleic Acids -- 1.15.2 VLPs Produced from Plants -- 1.16 Vaccines Targeting Latent Viruses -- 1.16.1 Vaccines Targeting Shingles -- 1.16.2 Human Cytomegalovirus (CMV) -- 1.16.3 Epstein-Barr Virus (EBV) 1.17 The Unmet Medical Need -- 1.18 Herd Immunity -- References -- Chapter 2 Preclinical Safety Assessment Considerations for Vaccine Development -- Introduction -- 2.2 General Considerations -- 2.2.1 Regulatory Guidelines for the Non-clinical Safety Assessment of Vaccines and Adjuvants -- 2.2.2 Vaccine Modalities -- 2.2.3 Antigen -- 2.2.4 Adjuvant -- 2.3 Vaccine Study Design -- 2.3.1 Test Article -- 2.3.2 Species Selection -- 2.3.3 Study Groups -- 2.3.4 Dose, Dose Volume, and Administration Location -- 2.3.5 Dose Number and Dosing Interval -- 2.3.6 In-life Assessments 2.3.7 Anatomical Pathology -- 2.4 Genotoxicity and Carcinogenicity Studies -- 2.5 Biodistribution Studies -- 2.6 Neurovirulence Studies -- 2.7 Reproductive Toxicology Studies -- 2.8 Conclusion -- References -- Chapter 3 Clinical Trials in the Development of Vaccines for Infectious Diseases -- 3.1 Types of Vaccines and Populations for Immunisation -- 3.2 Staging Clinical Trials Throughout a Development Programme -- 3.3 Immunogenicity -- 3.3.1 Types of Antibody Assay -- 3.3.2 How Antibody Values are Expressed -- 3.3.3 What Does an Antibody Response Mean? 3.3.4 CellularMethods for Assessing Immunogenicity -- 3.3.5 Limits to Blood Sample Volumes -- 3.3.6 Clinical Trials That Use Immunogenicity Endpoints -- 3.4 Efficacy -- 3.4.1 Defining Efficacy -- 3.4.2 Defining Cases Within an Efficacy Trial -- 3.4.3 Selection of Subjects for Efficacy Trials -- 3.4.4 Efficacy Study Design -- 3.4.5 Non-pivotal Efficacy Studies -- 3.4.6 Controlled Human Infection Models -- 3.5 Safety -- 3.5.1 Reactogenicity -- 3.5.2 Other Adverse Events -- 3.6 Conclusion -- Postscript -- References -- Chapter 4 Clinical Trials in Immunotherapeutic Vaccine Development |
| ctrlnum | (OCoLC)1350707644 |
| dewey-full | 615.3/72 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.3/72 |
| dewey-search | 615.3/72 |
| dewey-sort | 3615.3 272 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05280cam a2200637 i 4500</leader><controlfield tag="001">ZDB-4-EBA-on1350707644</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |n|||||||||</controlfield><controlfield tag="008">221113s2022 enk o 000 0 eng d</controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">YDX</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">YDX</subfield><subfield code="d">N$T</subfield><subfield code="d">UIU</subfield><subfield code="d">EBLCP</subfield><subfield code="d">UKRSC</subfield><subfield code="d">UKAHL</subfield><subfield code="d">OCLCF</subfield><subfield code="d">OCLCO</subfield><subfield code="d">GZM</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">1354281945</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781839162589</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1839162589</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781839162572</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1839162570</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9781788018777</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">178801877X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1350707644</subfield><subfield code="z">(OCoLC)1354281945</subfield></datafield><datafield tag="037" ind1=" " ind2=" "><subfield code="a">6102:5944</subfield><subfield code="b">Royal Society of Chemistry</subfield><subfield code="n">http://www.rsc.org/spr</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RM281</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">071000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">SCI</subfield><subfield code="x">013040</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">615.3/72</subfield><subfield code="2">23</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Vaccine development :</subfield><subfield code="b">from concept to clinic /</subfield><subfield code="c">edited by A. Krishna Prasad.</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Cambridge :</subfield><subfield code="b">Royal Society of Chemstry,</subfield><subfield code="c">2022.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Drug development and pharmaceutical science</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Cover -- Dedication -- Foreword -- Contents -- Chapter 1 Vaccine Development: From Concept to Clinic -- 1.1 Introduction -- 1.2 Preclinical Safety Assessment Considerations -- 1.3 Clinical Trials in the Development of Vaccines -- 1.5 High-throughput Assays for Clinical Development -- 1.6 Complexity in the Development of Multivalent Vaccines: Virus-like Particle-based Vaccines -- 1.7 Cell Culture-based Influenza Vaccine Development -- 1.8 Conjugate Vaccines: Design and Development Considerations -- 1.9 Vaccine Adjuvants</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">1.10 Development Considerations for Final Dosage Forms: Mucosal Bacterial Vaccines -- 1.11 Exploiting Glycans for Vaccine Design -- 1.12 Public-Private Partnerships for Vaccine Development -- 1.13 Structure-based Vaccine Design: The New Frontier -- 1.14 Vaccines to Target Antimicrobial Resistance -- 1.15 Technologies Revolutionizing Vaccines -- 1.15.1 Vaccines Based on Nucleic Acids -- 1.15.2 VLPs Produced from Plants -- 1.16 Vaccines Targeting Latent Viruses -- 1.16.1 Vaccines Targeting Shingles -- 1.16.2 Human Cytomegalovirus (CMV) -- 1.16.3 Epstein-Barr Virus (EBV)</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">1.17 The Unmet Medical Need -- 1.18 Herd Immunity -- References -- Chapter 2 Preclinical Safety Assessment Considerations for Vaccine Development -- Introduction -- 2.2 General Considerations -- 2.2.1 Regulatory Guidelines for the Non-clinical Safety Assessment of Vaccines and Adjuvants -- 2.2.2 Vaccine Modalities -- 2.2.3 Antigen -- 2.2.4 Adjuvant -- 2.3 Vaccine Study Design -- 2.3.1 Test Article -- 2.3.2 Species Selection -- 2.3.3 Study Groups -- 2.3.4 Dose, Dose Volume, and Administration Location -- 2.3.5 Dose Number and Dosing Interval -- 2.3.6 In-life Assessments</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">2.3.7 Anatomical Pathology -- 2.4 Genotoxicity and Carcinogenicity Studies -- 2.5 Biodistribution Studies -- 2.6 Neurovirulence Studies -- 2.7 Reproductive Toxicology Studies -- 2.8 Conclusion -- References -- Chapter 3 Clinical Trials in the Development of Vaccines for Infectious Diseases -- 3.1 Types of Vaccines and Populations for Immunisation -- 3.2 Staging Clinical Trials Throughout a Development Programme -- 3.3 Immunogenicity -- 3.3.1 Types of Antibody Assay -- 3.3.2 How Antibody Values are Expressed -- 3.3.3 What Does an Antibody Response Mean?</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">3.3.4 CellularMethods for Assessing Immunogenicity -- 3.3.5 Limits to Blood Sample Volumes -- 3.3.6 Clinical Trials That Use Immunogenicity Endpoints -- 3.4 Efficacy -- 3.4.1 Defining Efficacy -- 3.4.2 Defining Cases Within an Efficacy Trial -- 3.4.3 Selection of Subjects for Efficacy Trials -- 3.4.4 Efficacy Study Design -- 3.4.5 Non-pivotal Efficacy Studies -- 3.4.6 Controlled Human Infection Models -- 3.5 Safety -- 3.5.1 Reactogenicity -- 3.5.2 Other Adverse Events -- 3.6 Conclusion -- Postscript -- References -- Chapter 4 Clinical Trials in Immunotherapeutic Vaccine Development</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Utilising successful case studies Vaccine Development will provide insight to the issues scientists face when producing a vaccine, the steps involved and will serve as an ideal reference tool regarding state-of-the-art vaccine development.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Vaccines.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85141718</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Drug development.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh97007921</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Vaccines</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D014612</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Vaccins.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Médicaments</subfield><subfield code="x">Développement.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drug development</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Vaccines</subfield><subfield code="2">fast</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Prasad, A. Krishna,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="z">9781788018777</subfield><subfield code="w">(OCoLC)1197720173</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">RSC Drug development and pharmaceutical science.</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=3453660</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Askews and Holts Library Services</subfield><subfield code="b">ASKH</subfield><subfield code="n">AH39380813</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest Ebook Central</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL7152694</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">303250344</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">3453660</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">18383957</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-4-EBA-on1350707644 |
| illustrated | Not Illustrated |
| indexdate | 2024-11-27T13:30:39Z |
| institution | BVB |
| isbn | 9781839162589 1839162589 9781839162572 1839162570 |
| language | English |
| oclc_num | 1350707644 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource |
| psigel | ZDB-4-EBA |
| publishDate | 2022 |
| publishDateSearch | 2022 |
| publishDateSort | 2022 |
| publisher | Royal Society of Chemstry, |
| record_format | marc |
| series | RSC Drug development and pharmaceutical science. |
| series2 | Drug development and pharmaceutical science |
| spelling | Vaccine development : from concept to clinic / edited by A. Krishna Prasad. Cambridge : Royal Society of Chemstry, 2022. 1 online resource text txt rdacontent computer c rdamedia online resource cr rdacarrier Drug development and pharmaceutical science Cover -- Dedication -- Foreword -- Contents -- Chapter 1 Vaccine Development: From Concept to Clinic -- 1.1 Introduction -- 1.2 Preclinical Safety Assessment Considerations -- 1.3 Clinical Trials in the Development of Vaccines -- 1.5 High-throughput Assays for Clinical Development -- 1.6 Complexity in the Development of Multivalent Vaccines: Virus-like Particle-based Vaccines -- 1.7 Cell Culture-based Influenza Vaccine Development -- 1.8 Conjugate Vaccines: Design and Development Considerations -- 1.9 Vaccine Adjuvants 1.10 Development Considerations for Final Dosage Forms: Mucosal Bacterial Vaccines -- 1.11 Exploiting Glycans for Vaccine Design -- 1.12 Public-Private Partnerships for Vaccine Development -- 1.13 Structure-based Vaccine Design: The New Frontier -- 1.14 Vaccines to Target Antimicrobial Resistance -- 1.15 Technologies Revolutionizing Vaccines -- 1.15.1 Vaccines Based on Nucleic Acids -- 1.15.2 VLPs Produced from Plants -- 1.16 Vaccines Targeting Latent Viruses -- 1.16.1 Vaccines Targeting Shingles -- 1.16.2 Human Cytomegalovirus (CMV) -- 1.16.3 Epstein-Barr Virus (EBV) 1.17 The Unmet Medical Need -- 1.18 Herd Immunity -- References -- Chapter 2 Preclinical Safety Assessment Considerations for Vaccine Development -- Introduction -- 2.2 General Considerations -- 2.2.1 Regulatory Guidelines for the Non-clinical Safety Assessment of Vaccines and Adjuvants -- 2.2.2 Vaccine Modalities -- 2.2.3 Antigen -- 2.2.4 Adjuvant -- 2.3 Vaccine Study Design -- 2.3.1 Test Article -- 2.3.2 Species Selection -- 2.3.3 Study Groups -- 2.3.4 Dose, Dose Volume, and Administration Location -- 2.3.5 Dose Number and Dosing Interval -- 2.3.6 In-life Assessments 2.3.7 Anatomical Pathology -- 2.4 Genotoxicity and Carcinogenicity Studies -- 2.5 Biodistribution Studies -- 2.6 Neurovirulence Studies -- 2.7 Reproductive Toxicology Studies -- 2.8 Conclusion -- References -- Chapter 3 Clinical Trials in the Development of Vaccines for Infectious Diseases -- 3.1 Types of Vaccines and Populations for Immunisation -- 3.2 Staging Clinical Trials Throughout a Development Programme -- 3.3 Immunogenicity -- 3.3.1 Types of Antibody Assay -- 3.3.2 How Antibody Values are Expressed -- 3.3.3 What Does an Antibody Response Mean? 3.3.4 CellularMethods for Assessing Immunogenicity -- 3.3.5 Limits to Blood Sample Volumes -- 3.3.6 Clinical Trials That Use Immunogenicity Endpoints -- 3.4 Efficacy -- 3.4.1 Defining Efficacy -- 3.4.2 Defining Cases Within an Efficacy Trial -- 3.4.3 Selection of Subjects for Efficacy Trials -- 3.4.4 Efficacy Study Design -- 3.4.5 Non-pivotal Efficacy Studies -- 3.4.6 Controlled Human Infection Models -- 3.5 Safety -- 3.5.1 Reactogenicity -- 3.5.2 Other Adverse Events -- 3.6 Conclusion -- Postscript -- References -- Chapter 4 Clinical Trials in Immunotherapeutic Vaccine Development Utilising successful case studies Vaccine Development will provide insight to the issues scientists face when producing a vaccine, the steps involved and will serve as an ideal reference tool regarding state-of-the-art vaccine development. Vaccines. http://id.loc.gov/authorities/subjects/sh85141718 Drug development. http://id.loc.gov/authorities/subjects/sh97007921 Vaccines https://id.nlm.nih.gov/mesh/D014612 Vaccins. Médicaments Développement. Drug development fast Vaccines fast Prasad, A. Krishna, editor. Print version: 9781788018777 (OCoLC)1197720173 RSC Drug development and pharmaceutical science. FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=3453660 Volltext |
| spellingShingle | Vaccine development : from concept to clinic / RSC Drug development and pharmaceutical science. Cover -- Dedication -- Foreword -- Contents -- Chapter 1 Vaccine Development: From Concept to Clinic -- 1.1 Introduction -- 1.2 Preclinical Safety Assessment Considerations -- 1.3 Clinical Trials in the Development of Vaccines -- 1.5 High-throughput Assays for Clinical Development -- 1.6 Complexity in the Development of Multivalent Vaccines: Virus-like Particle-based Vaccines -- 1.7 Cell Culture-based Influenza Vaccine Development -- 1.8 Conjugate Vaccines: Design and Development Considerations -- 1.9 Vaccine Adjuvants 1.10 Development Considerations for Final Dosage Forms: Mucosal Bacterial Vaccines -- 1.11 Exploiting Glycans for Vaccine Design -- 1.12 Public-Private Partnerships for Vaccine Development -- 1.13 Structure-based Vaccine Design: The New Frontier -- 1.14 Vaccines to Target Antimicrobial Resistance -- 1.15 Technologies Revolutionizing Vaccines -- 1.15.1 Vaccines Based on Nucleic Acids -- 1.15.2 VLPs Produced from Plants -- 1.16 Vaccines Targeting Latent Viruses -- 1.16.1 Vaccines Targeting Shingles -- 1.16.2 Human Cytomegalovirus (CMV) -- 1.16.3 Epstein-Barr Virus (EBV) 1.17 The Unmet Medical Need -- 1.18 Herd Immunity -- References -- Chapter 2 Preclinical Safety Assessment Considerations for Vaccine Development -- Introduction -- 2.2 General Considerations -- 2.2.1 Regulatory Guidelines for the Non-clinical Safety Assessment of Vaccines and Adjuvants -- 2.2.2 Vaccine Modalities -- 2.2.3 Antigen -- 2.2.4 Adjuvant -- 2.3 Vaccine Study Design -- 2.3.1 Test Article -- 2.3.2 Species Selection -- 2.3.3 Study Groups -- 2.3.4 Dose, Dose Volume, and Administration Location -- 2.3.5 Dose Number and Dosing Interval -- 2.3.6 In-life Assessments 2.3.7 Anatomical Pathology -- 2.4 Genotoxicity and Carcinogenicity Studies -- 2.5 Biodistribution Studies -- 2.6 Neurovirulence Studies -- 2.7 Reproductive Toxicology Studies -- 2.8 Conclusion -- References -- Chapter 3 Clinical Trials in the Development of Vaccines for Infectious Diseases -- 3.1 Types of Vaccines and Populations for Immunisation -- 3.2 Staging Clinical Trials Throughout a Development Programme -- 3.3 Immunogenicity -- 3.3.1 Types of Antibody Assay -- 3.3.2 How Antibody Values are Expressed -- 3.3.3 What Does an Antibody Response Mean? 3.3.4 CellularMethods for Assessing Immunogenicity -- 3.3.5 Limits to Blood Sample Volumes -- 3.3.6 Clinical Trials That Use Immunogenicity Endpoints -- 3.4 Efficacy -- 3.4.1 Defining Efficacy -- 3.4.2 Defining Cases Within an Efficacy Trial -- 3.4.3 Selection of Subjects for Efficacy Trials -- 3.4.4 Efficacy Study Design -- 3.4.5 Non-pivotal Efficacy Studies -- 3.4.6 Controlled Human Infection Models -- 3.5 Safety -- 3.5.1 Reactogenicity -- 3.5.2 Other Adverse Events -- 3.6 Conclusion -- Postscript -- References -- Chapter 4 Clinical Trials in Immunotherapeutic Vaccine Development Vaccines. http://id.loc.gov/authorities/subjects/sh85141718 Drug development. http://id.loc.gov/authorities/subjects/sh97007921 Vaccines https://id.nlm.nih.gov/mesh/D014612 Vaccins. Médicaments Développement. Drug development fast Vaccines fast |
| subject_GND | http://id.loc.gov/authorities/subjects/sh85141718 http://id.loc.gov/authorities/subjects/sh97007921 https://id.nlm.nih.gov/mesh/D014612 |
| title | Vaccine development : from concept to clinic / |
| title_auth | Vaccine development : from concept to clinic / |
| title_exact_search | Vaccine development : from concept to clinic / |
| title_full | Vaccine development : from concept to clinic / edited by A. Krishna Prasad. |
| title_fullStr | Vaccine development : from concept to clinic / edited by A. Krishna Prasad. |
| title_full_unstemmed | Vaccine development : from concept to clinic / edited by A. Krishna Prasad. |
| title_short | Vaccine development : |
| title_sort | vaccine development from concept to clinic |
| title_sub | from concept to clinic / |
| topic | Vaccines. http://id.loc.gov/authorities/subjects/sh85141718 Drug development. http://id.loc.gov/authorities/subjects/sh97007921 Vaccines https://id.nlm.nih.gov/mesh/D014612 Vaccins. Médicaments Développement. Drug development fast Vaccines fast |
| topic_facet | Vaccines. Drug development. Vaccines Vaccins. Médicaments Développement. Drug development |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=3453660 |
| work_keys_str_mv | AT prasadakrishna vaccinedevelopmentfromconcepttoclinic |